-
The rapidly spreading variants share the spike N501Y substitution, which is of particular concern as it increases cell entry and receptor binding.
-
The ACTIV-2 trial will initially enrol 220 participants with mild or moderate COVID-19 who are at risk for disease progression.
-
The Moderna vaccine is the second COVID-19 vaccine to receive approval from the European Medicines Agency.
COVID-19-Wochenhighlights aus der ganzen Welt: Israel führt das Impfrennen an, neue Virusvarianten ...